Strand Therapeutics
Programmable mRNA Therapeutics
1 open roleProgrammable mRNA TherapeuticsBoston, United States200 employees$256M raisedEst. 2017
Kinnevik
Regeneron Ventures
Amgen Ventures
Eli Lilly and Company
ICONIQ Capital
Alderline Group
About Strand Therapeutics
- Strand Therapeutics is an early-stage biotechnology company utilizing synthetic biology to genetically program mRNA.
- They are developing the first platform for creating programmable, long-acting mRNA therapeutics to deliver precise, multi-functional, and potentially curative therapies for patients.
Strand Therapeutics is listed on Rocketlist with 1 active role. The company is categorized as Programmable mRNA Therapeutics in BioTech. Strand Therapeutics is at Series B stage, with a B2C business model, headquartered in Boston, United States. Strand Therapeutics was founded in 2017 and has 200 employees. Strand Therapeutics has raised $256M. Active roles are refreshed daily from public hiring sources.